JP2013540719A5 - - Google Patents

Download PDF

Info

Publication number
JP2013540719A5
JP2013540719A5 JP2013527258A JP2013527258A JP2013540719A5 JP 2013540719 A5 JP2013540719 A5 JP 2013540719A5 JP 2013527258 A JP2013527258 A JP 2013527258A JP 2013527258 A JP2013527258 A JP 2013527258A JP 2013540719 A5 JP2013540719 A5 JP 2013540719A5
Authority
JP
Japan
Prior art keywords
individual
less
composition
compound
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013527258A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013540719A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/049936 external-priority patent/WO2012030939A1/en
Publication of JP2013540719A publication Critical patent/JP2013540719A/ja
Publication of JP2013540719A5 publication Critical patent/JP2013540719A5/ja
Pending legal-status Critical Current

Links

JP2013527258A 2010-09-01 2011-08-31 腎欠陥を有する個体へのロルカセリンの投与 Pending JP2013540719A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40262810P 2010-09-01 2010-09-01
US61/402,628 2010-09-01
US40314910P 2010-09-10 2010-09-10
US61/403,149 2010-09-10
PCT/US2011/049936 WO2012030939A1 (en) 2010-09-01 2011-08-31 Administration of lorcaserin to individuals with renal impairment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016050724A Division JP2016106148A (ja) 2010-09-01 2016-03-15 腎欠陥を有する個体へのロルカセリンの投与

Publications (2)

Publication Number Publication Date
JP2013540719A JP2013540719A (ja) 2013-11-07
JP2013540719A5 true JP2013540719A5 (cg-RX-API-DMAC10.html) 2014-10-16

Family

ID=44653552

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013527258A Pending JP2013540719A (ja) 2010-09-01 2011-08-31 腎欠陥を有する個体へのロルカセリンの投与
JP2016050724A Pending JP2016106148A (ja) 2010-09-01 2016-03-15 腎欠陥を有する個体へのロルカセリンの投与
JP2017093900A Withdrawn JP2017132811A (ja) 2010-09-01 2017-05-10 腎欠陥を有する個体へのロルカセリンの投与
JP2018226624A Pending JP2019031577A (ja) 2010-09-01 2018-12-03 腎欠陥を有する個体へのロルカセリンの投与

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016050724A Pending JP2016106148A (ja) 2010-09-01 2016-03-15 腎欠陥を有する個体へのロルカセリンの投与
JP2017093900A Withdrawn JP2017132811A (ja) 2010-09-01 2017-05-10 腎欠陥を有する個体へのロルカセリンの投与
JP2018226624A Pending JP2019031577A (ja) 2010-09-01 2018-12-03 腎欠陥を有する個体へのロルカセリンの投与

Country Status (14)

Country Link
US (3) US8999970B2 (cg-RX-API-DMAC10.html)
EP (2) EP2611449A1 (cg-RX-API-DMAC10.html)
JP (4) JP2013540719A (cg-RX-API-DMAC10.html)
KR (2) KR20140091458A (cg-RX-API-DMAC10.html)
CN (1) CN103347523A (cg-RX-API-DMAC10.html)
AU (3) AU2011296015B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013004707A2 (cg-RX-API-DMAC10.html)
CA (1) CA2808890A1 (cg-RX-API-DMAC10.html)
EA (1) EA201390335A1 (cg-RX-API-DMAC10.html)
HK (1) HK1210419A1 (cg-RX-API-DMAC10.html)
MX (1) MX2013002418A (cg-RX-API-DMAC10.html)
NZ (2) NZ630494A (cg-RX-API-DMAC10.html)
SG (2) SG188365A1 (cg-RX-API-DMAC10.html)
WO (1) WO2012030939A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822727B2 (en) * 2008-03-04 2014-09-02 Arena Pharmaceuticals, Inc. Processes for the preparation of intermediates related to the 5-HT2C agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
WO2011153206A1 (en) 2010-06-02 2011-12-08 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-ht2c receptor agonists
US20130267500A1 (en) * 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
JP2013539470A (ja) 2010-09-01 2013-10-24 アリーナ ファーマシューティカルズ， インコーポレイテッド ロルカセリンと光学活性な酸との塩
KR20180118801A (ko) 2010-09-01 2018-10-31 에자이 알앤드디 매니지먼트 가부시키가이샤 체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태
EA201390335A1 (ru) * 2010-09-01 2013-09-30 Арена Фармасьютикалз, Инк. Введение лоркасерина индивидуумам с почечной недостаточностью
KR20130101524A (ko) * 2010-09-01 2013-09-13 아레나 파마슈티칼스, 인크. 5-ｈｔ2ｃ 아고니스트의 비-흡습성 염
RU2674670C1 (ru) 2012-10-09 2018-12-12 Арена Фармасьютикалз, Инк. Способ коррекции массы тела
TW201618787A (zh) 2014-10-30 2016-06-01 艾尼納製藥公司 組合物及方法

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2900415A (en) 1954-12-14 1959-08-18 Lakeside Lab Inc Synthesized antispasmodic compounds
CH498122A (de) 1968-02-09 1970-10-31 Geigy Ag J R Verfahren zur Herstellung eines neuen Tetrahydroazepinderivates
CH481110A (de) 1967-02-17 1969-11-15 Geigy Ag J R Verfahren zur Herstellung von 1,2,4,5-Tetrahydro-3-azepinen
CH500194A (de) 1968-02-15 1970-12-15 Ciba Geigy Ag Verfahren zur Herstellung von Tetrahydroazepinderivaten
US4233217A (en) 1968-03-11 1980-11-11 Pennwalt Corporation Substituted 1,2,4,5-tetrahydro-3H, 3 benzazepines
CA974989A (en) 1968-03-11 1975-09-23 Wallace And Tiernan Inc. Process for preparing 1,2,4,5-tetrahydro-3h,3-benzazepines and products obtained thereby
FR314F (cg-RX-API-DMAC10.html) 1968-03-22 1970-05-25
FR7736M (cg-RX-API-DMAC10.html) 1968-09-02 1970-03-09
US3716639A (en) 1970-03-11 1973-02-13 Ciba Geigy Corp Anorexigenic tetrahydrobenzazepines
US3795683A (en) 1970-08-19 1974-03-05 Hoffmann La Roche 2,3,4,5-tetrahydro-1h-3-benzazepines
LU65954A1 (cg-RX-API-DMAC10.html) 1972-08-25 1974-03-07
US4210749A (en) 1974-11-12 1980-07-01 Pennwalt Corporation Substituted 1,2,4,5-tetrahydro-3H,3 benzazepines
SE7510988L (sv) 1975-10-01 1977-04-02 Draco Ab Nya farmaceutiskt aktiva foreningar
DE2627479C2 (de) 1976-06-18 1983-09-22 Bergwerksverband Gmbh, 4300 Essen Verwendung eines Formkokses als Adsorptionsmittel für Schwefeloxide aus Abgasen
US4111957A (en) 1977-02-02 1978-09-05 Smithkline Corporation Substituted 1-thienyl and furyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds
US4108989A (en) 1977-04-01 1978-08-22 Smithkline Corporation 2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diones
DE2758001A1 (de) 1977-12-24 1979-07-12 Hoechst Ag Cephalosporinderivate und verfahren zu ihrer herstellung
CA1090797A (en) 1978-06-20 1980-12-02 Kenneth G. Holden Substituted 1-thienyl and furyl-2,3,4,5-tetrahydro-1h- 3-benzazepine compounds
AU515236B2 (en) 1978-06-26 1981-03-26 Smithkline Corporation Substituted-1-thienyl and furyl-2,3,4,5-tetrahydro-14-3 benzazepine derivatives
ZA792785B (en) 1978-07-07 1980-08-27 Smithkline Corp Mercapto substituted-2,3,4,5-tetrahydro-1h-3-benzazepines
IE50355B1 (en) 1979-10-20 1986-04-02 Wyeth John & Brother Ltd Morpholine derivatives
US4477378A (en) 1980-02-05 1984-10-16 Schering Corp. Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
ZA827887B (en) 1981-11-27 1983-11-30 Smithkline Beckman Corp Pharmaceutical compositions and method of producing alpha2 antagonism
EP0080779B1 (en) 1981-11-27 1986-07-16 Smithkline Beckman Corporation 3-benzazepines as alpha-2 antagonists
FR2518544A1 (fr) 1981-12-22 1983-06-24 Lipha Benzodiazepines-1,3 thione-2, procede de preparation et medicament les contenant
FR2525603A1 (fr) 1982-04-27 1983-10-28 Adir Benzoazacycloalkyl-spiro-imidazolinines, leur preparation et leur application en therapeutique
US4988690A (en) 1982-06-14 1991-01-29 Hoechst-Roussel Pharmaceuticals Inc. 1-aryloxy-2,3,4,5-tetrahydro-3-benzazepines and anti-depressant use thereof
DE3418270A1 (de) 1984-05-17 1985-11-21 Dr. Karl Thomae Gmbh, 7950 Biberach Neue aminotetralinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US4541954A (en) 1984-09-05 1985-09-17 Smithkline Beckman Corporation Method for preparing 6-chloro-N-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
EP0204349A3 (de) 1985-06-01 1990-01-03 Dr. Karl Thomae GmbH Neue heteroaromatische Aminderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB8610668D0 (en) 1986-05-01 1986-06-04 Pfizer Ltd Anti-arrhythmia agents
EG18188A (en) 1986-05-01 1992-09-30 Pfizer Ltd Process for preparation anti-arhythmia agents
US4762845A (en) 1986-05-21 1988-08-09 Abbott Laboratories 7-(3-Substituted imino-1-pyrrolidinyl)-quinolone-3-carboxylic acids
EP0285287A3 (en) 1987-03-23 1990-08-16 Smithkline Beecham Corporation 3-benzazepine compounds for use in treating gastrointestinal motility disorders
US5015639A (en) 1987-03-27 1991-05-14 Schering Corporation Substituted benzazepines, their preparation and pharmaceutical compositions containing them
ZA882080B (en) 1987-03-27 1989-04-26 Schering Corp Substituted benzazepines,their preparation and pharmaceutical compositions containing them
US5247080A (en) 1987-03-27 1993-09-21 Schering Corporation Substituted benzazepines useful as intermediates for producing pharmaceutically active compounds
WO1988007858A1 (en) 1987-04-09 1988-10-20 Smithkline Beckman Corporation Sulfinyl and sulfonyl substituted 3-benzazepines
US4957914A (en) 1987-05-15 1990-09-18 Syntex (U.S.A.) Inc. 1,9-alkano-bridged-2,3,4,5-tetrahydro-1H-3-benzazepines
DK107688D0 (da) 1988-03-01 1988-03-01 Novo Industri As Carbaminsyreestere af substituerede 7-hydroxy-2,3,4,5-tetrahydro-1h-3-benzazepiner
US5422355A (en) 1989-06-02 1995-06-06 John Wyeth & Brother, Limited Composition for treating depression with (N-heteroaryl)alkylamines
US5178786A (en) 1989-08-04 1993-01-12 The Lubrizol Corporation Corrosion-inhibiting compositions and functional fluids containing same
MTP1076B (en) 1990-01-12 1991-09-30 Ciba Geigy Ag Hemihydrate
FI923458A0 (fi) 1990-02-02 1992-07-31 Schering Corp 4,5-cykloalkano-3-benzazepin-7-ol- derivat och deras anvaendning.
CA2037162A1 (en) 1990-03-12 1991-09-13 Steven Howard Shaber Heterocyclicacetonitriles and fungicidal use
ZA914536B (en) 1990-06-15 1992-03-25 Schering Corp 8-lower alkyl-5-cycloalkyl or 5-cycloakenyl substituted benzazepines and pharmaceutical compositions containing them
US5275915A (en) 1991-06-05 1994-01-04 Dainippon Ink And Chemicals, Inc. Developer for light-sensitive material
WO1993000094A2 (en) 1991-06-21 1993-01-07 Smithkline Beecham Plc Use of tetrahydrobenzazepine derivatives for the treatment of portal hypertension and migraine
GB9116824D0 (en) 1991-08-05 1991-09-18 Smithkline Beecham Corp Chemical compounds
EP0558824A1 (en) 1992-02-04 1993-09-08 Duphar International Research B.V Method for the preparation of vicinal aminoalcohols and optically active O-protected derivatives thereof
US5241065A (en) 1992-02-25 1993-08-31 Schering Corporation 2,3,4,5-tetrahydro-1h-3-benzazepines having anti-psychotic activity
JPH05339263A (ja) 1992-06-08 1993-12-21 Wakunaga Pharmaceut Co Ltd ジヒドロピリジン誘導体
JP2987258B2 (ja) 1992-07-13 1999-12-06 沖電気工業株式会社 非同期転送モード通信網におけるトラヒック監視方式
JPH06298746A (ja) 1993-04-19 1994-10-25 Showa Denko Kk 環状イミド酸エステルの製造法
AU7177694A (en) 1993-06-23 1995-01-17 Cambridge Neuroscience, Inc. Sigma receptor ligands and the use thereof
US5387685A (en) 1993-07-16 1995-02-07 American Cyanamid Co MDR reversal agents
GB9322976D0 (en) 1993-11-08 1994-01-05 Pfizer Ltd Therapeutic agents
DE4419247A1 (de) 1994-06-01 1995-12-07 Merckle Gmbh Sulfonylierte Pyrrolizincarbonsäureamide und deren Anwendung in der Pharmazie
DE4419246A1 (de) 1994-06-01 1995-12-07 Merckle Gmbh Heteroarylsubstituierte Pyrrolizinverbindungen und deren Anwendung in der Pharmazie
DE4419315A1 (de) 1994-06-01 1995-12-07 Merckle Gmbh Heteropyrrolizinverbindungen und deren Anwendung in der Pharmazie
DE4427838A1 (de) 1994-08-05 1996-02-08 Thomae Gmbh Dr K Kondensierte Azepinderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE4429079A1 (de) 1994-08-17 1996-02-22 Thomae Gmbh Dr K Cyclische Harnstoffderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JPH08134048A (ja) 1994-11-08 1996-05-28 Sumitomo Chem Co Ltd オキサゾリン類の製造法
DE19510566A1 (de) 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
GB9508622D0 (en) 1995-04-28 1995-06-14 Pfizer Ltd Therapeutic agants
US5958543A (en) 1995-07-07 1999-09-28 Stor Media,Inc. Micro-texturing for sputtered, thin film magnetic media disks utilizing titanium sputtered in the presence of hydrogen to form micro-texturing
JPH0930960A (ja) 1995-07-18 1997-02-04 Takasago Internatl Corp 真菌感染症治療剤
CA2190708A1 (en) 1995-12-08 1997-06-09 Johannes Aebi Aminoalkyl substituted benzo-heterocyclic compounds
US5892116A (en) 1996-01-03 1999-04-06 Georgetown University Gelators
US5925651A (en) 1996-04-03 1999-07-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5691362A (en) 1996-06-05 1997-11-25 Schering-Plough Corporation Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists
WO1998006701A1 (en) 1996-08-15 1998-02-19 Smithkline Beecham Corporation Il-8 receptor antagonists
US5908830A (en) 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
EP0973778A1 (en) 1997-03-07 2000-01-26 Novo Nordisk A/S 4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE
AUPP020297A0 (en) 1997-11-05 1997-11-27 University Of Melbourne, The A novel receptor, and compounds which bind thereto
DE69941777D1 (de) 1998-03-10 2010-01-21 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
KR100589474B1 (ko) 1998-03-26 2006-06-14 산텐 세이야꾸 가부시키가이샤 신규한 우레아 유도체
JP3603177B2 (ja) 1998-03-26 2004-12-22 参天製薬株式会社 新規ウレア誘導体
EP0987235B1 (en) 1998-08-25 2003-03-12 MERCK PATENT GmbH Method for the conversion of arenes or alkenes with iodoalkenes, aryl iodides or arenediazonium salts
US20080255093A1 (en) 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US20080103179A1 (en) 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
EP1074549B1 (en) 1999-08-06 2003-11-19 F. Hoffmann-La Roche Ag Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors
ES2209728T3 (es) 1999-08-06 2004-07-01 F. Hoffmann-La Roche Ag Tetrahidro-benzo(d)azepinas y su uso como antagonistas de receptores de glutamato metabotropico.
JP2001076413A (ja) 1999-09-06 2001-03-23 Sony Corp フレキシブル磁気ディスク用ヘッドスライダー
US6403657B1 (en) 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
DE10003708A1 (de) 2000-01-28 2001-08-02 Solvent Innovation Gmbh Neuartige chirale ionische Flüssigkeiten und Verfahren zu ihrer Darstellung in enantiomerenreiner oder enantiomerenangereicherter Form
CA2413134C (en) 2000-06-30 2010-05-11 Glaxo Group Limited Quinazoline ditosylate salt compounds
AR035369A1 (es) 2000-11-14 2004-05-12 Smithkline Beecham Plc Derivados de tetrahidrobenzazepina composiciones farmaceuticas que los comprenden, el uso de dichos derivados en la fabricacion de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos
DE10057751A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Carbamat-substituierte Pyrazolopyridinderivate
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
JPWO2002074746A1 (ja) 2001-03-16 2004-07-08 山之内製薬株式会社 ベンゾアゼピン誘導体
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
US7550261B2 (en) 2001-08-21 2009-06-23 Smithkline Beecham Corporation Method of screening for drug hypersensitivity reaction
JP2005514330A (ja) 2001-09-24 2005-05-19 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病治療のための置換アミン
EP1456178A1 (en) 2001-12-21 2004-09-15 Smithkline Beecham Plc 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders
AU2002367323A1 (en) 2001-12-28 2003-07-24 Bayer Pharmaceuticals Corporation Benzothieno (3,2-
CA2473740A1 (en) 2002-01-18 2003-07-31 David Solow-Cordero Methods of treating conditions associated with an edg receptor
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
AU2003228485A1 (en) 2002-04-12 2003-10-27 The University Of Chicago Farnesoid x-activated receptor agonists
US7105505B2 (en) 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
GB0224557D0 (en) 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
DE10261131A1 (de) 2002-12-20 2004-07-01 Grünenthal GmbH Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US8367657B2 (en) 2003-06-17 2013-02-05 Arena Pharmaceuticals, Inc. Processes for preparing 3-benzazepines
CN1805938B (zh) 2003-06-17 2010-06-16 艾尼纳制药公司 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
MXPA05013365A (es) 2003-06-20 2006-04-05 Arena Pharm Inc Derivados de n-fenil-piperazina y metodos para profilaxis o tratamiento de enfermedades asociadas con el receptor 5ht2c.
TW200510324A (en) 2003-08-11 2005-03-16 Lilly Co Eli 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist
WO2005042491A1 (en) 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
WO2005042490A1 (en) 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
CA2556390C (en) 2004-02-25 2012-10-02 Eli Lilly And Company 6-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
US7157445B2 (en) 2004-02-26 2007-01-02 Aventis Pharma S.A. Administration of enoxaparin sodium to patients with severe renal impairment
SE0401871D0 (sv) 2004-07-15 2004-07-15 Glucogene Medical Hfm Ab New compositions
MX2007001337A (es) 2004-08-02 2008-03-13 Genmedica Therapeutics Sl Compuestos para inhibir amina-oxidasas que contienen cobre y usos de los mismos.
WO2006043710A1 (ja) 2004-10-19 2006-04-27 Reverse Proteomics Research Institute Co., Ltd. 創薬標的タンパク質及び標的遺伝子、並びにスクリーニング方法
EP2149562A1 (en) 2004-12-21 2010-02-03 Arena Pharmaceuticals, Inc. method of preparing (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride hemihydrate
NZ589951A (en) 2004-12-23 2012-11-30 Arena Pharm Inc 5HT2C receptor modulator compositions and methods of use
CA2646044A1 (en) 2006-04-03 2007-10-25 Arena Pharmaceuticals, Inc. Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto
EP2099743B1 (en) * 2006-12-05 2014-08-27 Arena Pharmaceuticals, Inc. Processes for preparing (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates thereof
US8586634B2 (en) 2007-06-15 2013-11-19 University Of Florida Research Foundation, Inc. Therapeutic compounds
US20100317572A1 (en) 2007-12-20 2010-12-16 Neurosearch A/S Pharmaceutical composition comprising tesofensine or its analogue and an anti-obesity compound
WO2009097416A1 (en) 2008-01-29 2009-08-06 Vanda Pharmaceuticals, Inc. Imidazolylalkyl- pyridines as dbh inhibitors
US8822727B2 (en) 2008-03-04 2014-09-02 Arena Pharmaceuticals, Inc. Processes for the preparation of intermediates related to the 5-HT2C agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
US7608616B1 (en) 2008-06-03 2009-10-27 Questcor Pharmaceuticals, Inc. Methods for reducing the risk of an adverse drug interaction in a patient suffering from insomnia
WO2010148207A2 (en) 2009-06-18 2010-12-23 Arena Pharmaceuticals, Inc. Processes for the preparation of 5-ht2c receptor agonists
KR20130138768A (ko) 2010-09-01 2013-12-19 아레나 파마슈티칼스, 인크. 5-ｈｔ2ｃ 아고니스트의 신속-용해성 투여 형태
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
JP2013539470A (ja) 2010-09-01 2013-10-24 アリーナ ファーマシューティカルズ， インコーポレイテッド ロルカセリンと光学活性な酸との塩
KR20180118801A (ko) 2010-09-01 2018-10-31 에자이 알앤드디 매니지먼트 가부시키가이샤 체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태
EA201390335A1 (ru) 2010-09-01 2013-09-30 Арена Фармасьютикалз, Инк. Введение лоркасерина индивидуумам с почечной недостаточностью
CN102126988A (zh) 2010-12-17 2011-07-20 张家港瀚康化工有限公司 4-(4-氯苯基)-2-溴甲基-2-苯基丁腈的制备方法

Similar Documents

Publication Publication Date Title
TWI632911B (zh) 腫瘤溶解症候群之治療劑及預防劑
Friedman et al. Hyponatremia in critical care patients: frequency, outcome, characteristics, and treatment with the vasopressin V2-receptor antagonist tolvaptan
JP2021059610A (ja) 処置法
JP2021532126A (ja) アルツハイマー病の治療及び予防方法
JP2013521303A5 (cg-RX-API-DMAC10.html)
JP6731915B2 (ja) 多発性硬化症治療用のシポニモドとラキニモドを含む組み合わせ
JP2020507611A5 (cg-RX-API-DMAC10.html)
KR20240148425A (ko) Cns-관련 장애의 치료를 위한 신경활성 스테로이드
WO2019160057A1 (ja) 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
JP2006518731A5 (cg-RX-API-DMAC10.html)
US20160058754A1 (en) Nalmefene for Treatment of Patients with Anxiety Disorder
KR20210024475A (ko) 질환 치료를 위한 릴루졸 경구 붕해 정제의 용도
WO2011085331A1 (en) Methods of providing weight loss therapy in patients with major depression
KR102311915B1 (ko) 만성 신장병의 진행 억제 또는 개선제
JP5416327B2 (ja) タキサンにより惹起される神経毒性を予防又は軽減するための薬剤
KR20180051560A (ko) 비만 및 비만 관련 장애의 치료를 위한 카나글리플로진 및 펜테르민을 포함하는 공동 요법
CN115605194A (zh) 过度炎症综合征的治疗
KR20220024821A (ko) 악성 종양의 치료 방법
Marino et al. The Drug Update: Recent drug approvals
AU3945193A (en) Compositions and methods for treating benign prostatic hypertrophy
US20170020867A1 (en) Use of masitinib for the treatment of crohn's disease
CN104053441B (zh) 用于预防或治疗高脂血症的药物组合物
WO2013069764A1 (ja) クレアチン組成物の摂取方法及び該摂取方法にて使用するクレアチン組成物並びに前記クレアチン組成物を使用して成るクレアチン含有薬剤及び食品
WO2003047591A1 (fr) Medicaments contre l'hypertension arterielle pulmonaire primitive
Ryan et al. Medications Indicated for Chronic Weight Management